Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Curr Opin Oncol. 2020 Jan;32(1):63-67. doi: 10.1097/CCO.0000000000000592.
The purpose of the review is to summarize the current and future role of chemotherapy in the treatment of patients with nonsmall cell lung cancer (NSCLC).
Chemotherapy has been established in early-stage, locally advanced and metastatic NSCLC. Patients with driver mutation-positive NSCLC receive tyrosine kinase inhibitors as first-line therapy and chemotherapy later during the course of their disease. Immune checkpoint inhibitors have entered clinical practice as single agents or in combination with chemotherapy. These novel treatments will supplement chemotherapy in all tumor stages of NSCLC.
Targeted drugs and immune checkpoint inhibitors are gaining increasing importance in the treatment of NSCLC. They will supplement but not replace chemotherapy in the future.
本综述旨在总结化疗在非小细胞肺癌（NSCLC）治疗中的当前和未来作用。
化疗已在早期、局部晚期和转移性 NSCLC 中确立。携带有驱动基因突变阳性 NSCLC 的患者接受酪氨酸激酶抑制剂作为一线治疗，在疾病进展过程中接受化疗。免疫检查点抑制剂已作为单一药物或与化疗联合应用于临床实践。这些新的治疗方法将在 NSCLC 的所有肿瘤分期中补充化疗。
靶向药物和免疫检查点抑制剂在 NSCLC 的治疗中越来越重要。它们将在未来补充而不是取代化疗。
